Zevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $20.00 at HC Wainwright

Zevra Therapeutics (NASDAQ:ZVRA) had its price target lifted by HC Wainwright from $18.00 to $20.00 in a research note released on Friday, Benzinga reports. They currently have a buy rating on the stock.

ZVRA has been the subject of several other reports. Canaccord Genuity Group reduced their price target on Zevra Therapeutics from $24.00 to $22.00 and set a buy rating for the company in a research report on Wednesday, September 18th. William Blair upgraded Zevra Therapeutics to a strong-buy rating in a research report on Friday, August 30th. Finally, Cantor Fitzgerald restated an overweight rating on shares of Zevra Therapeutics in a research report on Wednesday, August 14th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of Buy and a consensus price target of $21.25.

Zevra Therapeutics Price Performance

Shares of NASDAQ ZVRA opened at $8.06 on Friday. The stock has a market cap of $337.34 million, a PE ratio of -5.97 and a beta of 1.94. Zevra Therapeutics has a fifty-two week low of $3.89 and a fifty-two week high of $8.95. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00. The stock has a fifty day moving average of $7.04 and a 200-day moving average of $5.71.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The company had revenue of $4.45 million during the quarter, compared to analysts’ expectations of $4.08 million. Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. During the same quarter last year, the firm posted ($0.15) earnings per share. Equities research analysts anticipate that Zevra Therapeutics will post -1.58 earnings per share for the current year.

Insider Buying and Selling

In other Zevra Therapeutics news, Director Thomas Anderson bought 10,000 shares of Zevra Therapeutics stock in a transaction that occurred on Tuesday, July 16th. The stock was acquired at an average cost of $6.81 per share, for a total transaction of $68,100.00. Following the completion of the transaction, the director now directly owns 20,000 shares in the company, valued at $136,200. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders acquired a total of 22,000 shares of company stock worth $140,340 over the last ninety days. 2.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zevra Therapeutics

Several hedge funds have recently added to or reduced their stakes in ZVRA. Armistice Capital LLC bought a new stake in Zevra Therapeutics during the fourth quarter worth about $1,755,000. Sanctuary Advisors LLC bought a new stake in Zevra Therapeutics during the second quarter worth about $474,000. Vanguard Group Inc. lifted its stake in Zevra Therapeutics by 3.6% during the first quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock worth $9,883,000 after purchasing an additional 58,866 shares during the last quarter. Retirement Planning Co of New England Inc. lifted its stake in Zevra Therapeutics by 11.0% during the first quarter. Retirement Planning Co of New England Inc. now owns 430,193 shares of the company’s stock worth $2,495,000 after purchasing an additional 42,766 shares during the last quarter. Finally, Mystic Asset Management Inc. lifted its stake in Zevra Therapeutics by 15.4% during the first quarter. Mystic Asset Management Inc. now owns 266,297 shares of the company’s stock worth $1,545,000 after purchasing an additional 35,514 shares during the last quarter. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.